S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
The Next Big Crisis Is Here (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
The Next Big Crisis Is Here (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
The Next Big Crisis Is Here (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
The Next Big Crisis Is Here (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close

Editas Medicine - EDIT Price Target & Analyst Ratings

$9.57
+0.50 (+5.51%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$8.99
$9.77
50-Day Range
$7.81
$10.60
52-Week Range
$7.70
$21.59
Volume
1.45 million shs
Average Volume
1.78 million shs
Market Capitalization
$658.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.86

Editas Medicine Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 14 Analyst Ratings

Consensus Analyst Price Target

$16.86
76.15% Upside
High Prediction$36.00
Average Prediction$16.86
Low Prediction$7.00
TypeCurrent
1/28/22 to 1/28/23
1 Month Ago
12/29/21 to 12/29/22
3 Months Ago
10/30/21 to 10/30/22
1 Year Ago
1/28/21 to 1/28/22
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
6 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$16.86$15.46$24.78$50.00
Predicted Upside76.15% Upside35.43% Upside58.74% Upside14.94% Upside
Get Editas Medicine Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.


EDIT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EDIT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Editas Medicine Stock vs. The Competition

TypeEditas MedicineMedical CompaniesS&P 500
Consensus Rating Score
2.14
2.64
2.46
Consensus RatingHoldBuyHold
Predicted Upside76.15% Upside1,055.15% Upside9.96% Upside
News Sentiment RatingPositive News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/24/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight$8.00 ➝ $7.00-14.00%
1/23/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Bienkowski
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetMarket Perform$6.00 ➝ $7.00-14.43%
1/4/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$50.00 ➝ $36.00+326.54%
12/13/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$11.00+16.03%
12/6/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral$13.00+32.25%
11/21/2022Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$8.00-21.57%
11/18/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$18.00 ➝ $15.00+43.13%
11/18/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSector Perform$32.00 ➝ $14.00+27.16%
11/18/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$80.00 ➝ $35.00+217.89%
11/18/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$25.00 ➝ $18.00+63.49%
11/17/2022Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$43.00 ➝ $35.00+217.89%
11/17/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$28.00 ➝ $12.00+8.99%
8/4/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$16.00 ➝ $17.00-8.01%
5/24/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSell$10.00 ➝ $8.00-21.65%
9/30/2021Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold$65.00 ➝ $46.00+8.24%
2/28/2021JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSell$30.00-31.60%
1/7/2021Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
6/18/2020SunTrust Banks
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$45.00+50.55%
(Data available from 1/28/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












EDIT Price Target - Frequently Asked Questions

What is Editas Medicine's consensus rating and price target?

According to the issued ratings of 14 analysts in the last year, the consensus rating for Editas Medicine stock is Hold based on the current 2 sell ratings, 8 hold ratings and 4 buy ratings for EDIT. The average twelve-month price prediction for Editas Medicine is $16.86 with a high price target of $36.00 and a low price target of $7.00. Learn more on EDIT's analyst rating history.

Do Wall Street analysts like Editas Medicine more than its competitors?

Analysts like Editas Medicine less than other Medical companies. The consensus rating for Editas Medicine is Hold while the average consensus rating for medical companies is Buy. Learn more on how EDIT compares to other companies.

Is Editas Medicine being downgraded by Wall Street analysts?

Over the previous 90 days, Editas Medicine's stock had 2 downgrades by analysts.

Does Editas Medicine's stock price have much upside?

According to analysts, Editas Medicine's stock has a predicted upside of 55.82% based on their 12-month price targets.

What analysts cover Editas Medicine?

Stock Ratings Reports and Tools

This page (NASDAQ:EDIT) was last updated on 1/28/2023 by MarketBeat.com Staff